European Court of Justice. ECJ--2010/4--Association generale de l'industrie du medicament ASBL, Bayer SA, pfizer SA, Servier Benelux SA, Janssen Cilag SA (limited to C-471/07), Sanofi-Avnetis Belgium SA vs. Belgium Sanofi-Aventis Belgium SA (limited to C-472/07), 14 January 2010 (joined cases C-471/07 and C-472/07).

摘要

The judgement has been issued following preliminary rulings and concerns the interpretation of Article 4(1) of Directive 89/105/EEC relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems. In particular, it concerns the yearly review a Member State shall carry out in the event of a price freeze imposed on medicinal products.